Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol. 2002 Jul 01; 20(13):2995-3000.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.